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ttp://dx.doi.org/10.1016/j.ajpath.2014.02.025Diverse etiologic events are associated with the development of hepatocellular carcinoma. During
hepatocarcinogenesis, genetic events likely occur that subsequently cooperate with long-term expo-
sures to further drive the progression of hepatocellular carcinoma. In this study, the frequent loss of the
retinoblastoma (RB) tumor suppressor in hepatocellular carcinoma was modeled in response to diverse
hepatic stresses. Loss of RB did not signiﬁcantly affect the response to a steatotic stress as driven by a
methionine- and choline-deﬁcient diet. In addition, RB status did not signiﬁcantly inﬂuence the
response to peroxisome proliferators that can drive hepatomegaly and tumor development in rodents.
However, RB loss exhibited a highly signiﬁcant effect on the response to the xenobiotic1,4-Bis-[2-(3,5-
dichloropyridyloxy)] benzene. Loss of RB yielded a unique proliferative response to this agent, which
was distinct from both regenerative stresses and genotoxic carcinogens. Long-term exposure to 1,4-Bis-
[2-(3,5-dichloropyridyloxy)] benzene yielded profound tumor development in RB-deﬁcient livers that
was principally absent in RB-sufﬁcient tissue. These data demonstrate the context speciﬁcity of RB and
the key role RB plays in the suppression of hepatocellular carcinoma driven by xenobiotic stress.
(Am J Pathol 2014, 184: 1853e1859; http://dx.doi.org/10.1016/j.ajpath.2014.02.025)Supported by National Cancer Institute grant CA127387 (E.S.K.).
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Current address of C.R., PerkinElmer, Downer’s Grove, IL.Hepatocellular carcinoma (HCC) is the predominant mani-
festation of primary liver cancer and represents the third
leading cause of cancer deaths worldwide.1 HCC is unique
among cancers in that most cases can be traced to diverse
high-risk etiologic events.2 Unlike lung cancer or melanoma,
wherein smoking or solar exposure are predominating risks,
for HCC, multiple etiologic events can be driving the dis-
ease.1,2 Hepatitis B virus or hepatitis C virus infections have
diverse effects on liver biology but are the primary etiologic
events for HCC.2 Similarly, chronic alcoholism progressing
to liver cirrhosis is a well-known etiologic event for HCC.
Exposure to environmental carcinogens, such as aﬂatoxin
B1, can also lead to HCC1; furthermore, with the obesity
epidemic, nonalcoholic steatohepatitis cirrhosis is anticipated
to be a signiﬁcant etiologic factor for HCC.3
Despite the diversity of etiologic events, the prevailing
model for the development of HCC is that these processes
lead to mutational or epigenetic changes in cells of the liver
that initiate tumor development and facilitate disease pro-
gression.1,4e7 One would expect that given the chronicstigative Pathology.
.nature of HCC development, speciﬁc genetic events
occurring early in the disease could subsequently alter the
cellular response to etiologic events and thereby contribute
to disease initiation and progression. A key genetic event in
the etiology of HCC is loss of heterozygosity at 13q, which
occurs in approximately 20% of liver cancers.8 This locus
encodes the retinoblastoma (RB) tumor suppressor, RB1,
and sequencing, and other approaches have indicated that
mutation or homozygous deletion of RB1 occurs relatively
frequently in disease.9,10 RB is a key negative regulator of
cell cycle. Our group and others have found that RB1 loss
plays a key role in deregulating the response to genotoxic
carcinogens, allowing for inappropriate response to hep-
atocarcinogens, such as aﬂatoxin B1 and diethyl nitrosamine
Reed et al(DEN).11,12 This loss of cell cycle control is associated with
increased tumor burden in mice treated with such
agents.11,13,14 These results reinforced the concept that RB
is a functional tumor suppressor in mouse models. Inter-
estingly, RB1 loss in combination with the potent oncogene
MYC had veritably no effect on tumor development.15 In
addition, in combination with TP53 loss, RB deﬁciency
only served to enhance genotoxic-driven tumor develop-
ment.16 Therefore, whether the effects of RB deﬁciency are
speciﬁcally related to genotoxic stresses or generally
applicable to hepatocarcinogenesis remains unknown.
In rodent models, as in humans, there are multiple pathways
to HCC development.17e19 A variety of DNA-damaging
agents, such as DEN, are known genotoxic hepatocarci-
nogens. However, long-term exposure to a number of addi-
tional agents can lead to HCC in mice through diverse
mechanisms. For example, to mimic metabolic dysfunction,
mice are fed speciﬁc diets, such as a methionine cholinee
deﬁcient diet, to induce fatty liver.17 Similarly, there are xe-
nobiotics, such as phenobarbital and 1,4-Bis-[2-(3,5-
dichloropyridyloxy)] benzene (TCPOBOP), that modulate
the constitutive androstane receptor to drive liver tumorigen-
esis.17,20 Lastly, there are synthetic peroxisome proliferators
that serve as peroxisome proliferator-activated receptor
(PPAR) agonists that are potent rodent carcinogens.18,21
Although the human relevance of some rodent carcinogen
models is debatable, such models allow the ability to decipher
the interaction between genetic events and facets of liver
biology that are clearly germane to human disease (eg, fatty or
cirrhotic liver). We investigated how RB1 status inﬂuences the
response to multiple nongenotoxic carcinogenic stresses in
mouse models. These ﬁndings indicate that RB has stress
contextespeciﬁc activities but can serve to restrain tumor
development driven by nongenotoxic carcinogens.
Materials and Methods
Mouse Generation
Mice with liver-speciﬁc deletion ofRB1 (Rb1f/f;Alb-creþ) and
genetically similar controls without Cre-mediated recombi-
nation (Rb1f/f) were used in this study. All mice were 8 weeks
old at the time of analysis or the beginning of time course
experiments. The generation and genotyping of these mice
have been discussed previously.22 All experiments and pro-
tocols were conducted in accordance with the Guide for the
Care and Use of Laboratory Animals 8th edition (NIH) and
were approved by Thomas Jefferson University.
TCPOBOP Compound
TCPOBOP (Sigma-Aldrich, St. Louis, MO) was dissolved
in corn oil (Sigma-Aldrich) at a concentration of 0.6
mg/mL. The experimental solution was kept at room tem-
perature in a light-restricted container for no longer than 6
months.1854Wy-14,643 Compound and MCDD
Wy-14,643 (Cayman Chemical, Ann Arbor, MI) was solu-
bilized in dimethyl sulfoxide, and mice were given a
40 mg/kg dose (in corn oil) every 24 hours via gavage for
either 72 hours or 2 weeks, accordingly. The methionine-
and choline-deﬁcient diet (MCDD) was purchased from
Test Diet (St. Louis, MO) and made speciﬁc to our needs.
Short-Term Carcinogen Treatment
For acute TCPOBOP, DEN, and carbon tetrachloride (CCl4)
treatments, 8-week-old Rb1f/f and Rb1f/f and Alb-creþ lit-
termates received a single i.p. injection of 3 mg/kg TCPO-
BOP, 20 mg/kg DEN, or 10% CCl4 in corn oil. TCPOBOP
vehicle mice received an injection of an equivalent amount
of corn oil. Treated animals and matched controls were
sacriﬁced 24 (DEN), 48 (CCl4), 72, or 216 hours after
treatment. Body and liver weights were measured, and tis-
sue was separated for genotyping, sectioning, and protein
extraction. Tissue harvesting and preparation were per-
formed as previously described.22 Genetically similar mice
received a special MCDD, whereas vehicle mice continued
to receive regular chow. Mice were kept on the diet
consistently for 2 weeks. The mice were fasted 24 hours
before sacriﬁce, yet they still had unrestricted access to
water during this time. At the time of sacriﬁce, mice were
weighed and photographed, and then livers were excised,
weighed, and imaged in the same manner. Mice treated with
the PPARa8 activator Wy-14,643 received the drug via
gavage once a day for either 72 hours or 2 weeks. Vehicle
mice received an equivalent amount of corn oil for the same
duration. For all treatments, a subset of mice received a
single i.p. injection of 150 mg/kg 5-bromo-2-deoxyuridine
(BrdU; Sigma-Aldrich) dissolved in saline 1 hour before
sacriﬁce.
Long-Term TCPOBOP Treatment
Rb1f/f and Rb1f/f;Alb-creþ littermates were aged to 8 weeks
and then given long-term biweekly injections of TCPOBOP
for 24 weeks for a total of 12 injections. Experimental an-
imals were then sacriﬁced 5 weeks after the last TCPOBOP
injection. Control animals were aged to 32 weeks and
sacriﬁced in the same manner as experimental animals. As
described above, body and liver weights were measured,
and liver tissue was harvested in the same fashion. Tumor
burden was noted by counting visible, resectable tumors
before harvesting. In some cases, tumor tissue was excised
from the liver and harvested for separate analysis. Images
were also obtained from each liver for further analysis.
IHC, Immunoﬂuorescence, and Immunoblotting
After sacriﬁce, the left lobe of the liver was ﬁxed in 10%
neutral buffered formalin and mounted in parafﬁn wax forajp.amjpathol.org - The American Journal of Pathology
Figure 1 Mice with RB-sufﬁcient and RB-deﬁcient
livers were treated with TCPOBOP, Wy-14,643, and
MCDD. A: Effects on gene expression as determined by
real-time PCR analysis. B: Excised livers were weighed and
normalized to body weight. For each condition, at least
ﬁve livers were measured. C: Representative images of
liver tissue from mice treated with TCPOBOP, Wy-14,643,
and MCDD stained with H&E. Data are presented as
means  SD (A and B). *P < 0.05 versus untreated as
determined by Welch’s t-test. Original magniﬁcation:
20. UNT, untreated.
RB Suppresses Xenobiotic Carcinogenesissectioning. Each liver was sectioned at 5 mm and used as
follows. Commercially available monoclonal and polyclonal
antibodies against BrdU (Sigma-Aldrich) to analyze DNA
synthesis, phospho-histone H3 S10 (Millipore, Billerica,
MA) to monitor mitotic progression, and Ki-67 (Dako,
Glostrup, Denmark) for proliferation analysis were used for
immunohistochemical (IHC) staining. IHC staining pro-
tocols have been previously described.16,22 H&E staining
was performed via a standard protocol. Other sections of the
liver were ﬂash frozen for protein extraction. Liver nuclei
protein preparation and immunoblotting techniques were
previously described. Immunoblot antibodies were
commercially available: PCNA (P-10; Santa Cruz Biotech-
nology, Inc., Dallas, TX), MCM7 (141.2; Santa Cruz
Biotechnology, Inc.), and Lamin B (M-20; Santa Cruz
Biotechnology, Inc.).The American Journal of Pathology - ajp.amjpathol.orgStatistical Analysis
Slides were scored in a blind fashion for at least 600 hepa-
tocytes from several ﬁelds for each staining. For histologic
assessment, a veterinary pathologist scored slides in a blind
fashion (A.W.). Statistical signiﬁcance between groups was
calculated with a 2-tailed unpaired t-test. Differences were
classiﬁed as statistically signiﬁcant at P < 0.05.
Results
RB Status Has Limited Effect on Histologic Response to
Diverse Hepatic Stressors
Distinct etiologic events promote human liver cancer.1,2 To
determine how the loss of RB1 in the liver may impinge on1855
Figure 2 Mice with RB-sufﬁcient and RB-deﬁcient livers were treated
with TCPOBOP, Wy-14,643, and MCDD. A: Representative images show the
effects on proliferation as determined by BrdU incorporation. B: Quanti-
tation of BrdU incorporation from mice treated with the agents for the
times indicated. All data are from at least ﬁve livers. Data are presented as
means  SD. *P < 0.05 versus TCPOBOP-treated RB-sufﬁcient livers as
determined by Welch’s t-test. Original magniﬁcation: 20 (A).
Reed et althe response to diverse carcinogenic stresses, we used Rb1f/f
and Rb1f/f;Alb-cre mice. We have previously demonstrated
the effective liver-speciﬁc deletion of RB in this model.22
These mice were exposed to three agents: i) TCPOBOP, a
potent xenobiotic constitutive androstane receptor agonist
that can initiate and promote tumor development4; ii)
MCDD, which induces fatty liver in mice23; and iii) the
PPARa/g activator Wy-14,643, which is a potent mitogen
and carcinogen in rodent models.17
To probe the molecular response to each stress, we
initially investigated speciﬁc targets associated with prolif-
eration and fat accumulation. To monitor proliferation-
associated transcription, MCM7 RNA levels were
measured by quantitative RT-PCR. TCPOBOP resulted in
signiﬁcantly increased MCM7 RNA levels when compared
with the control mice (Figure 1A). The MCDD and treat-
ment with Wy-14,643 also induced MCM7 expression,
albeit to a lesser extent. Pgc1a is a marker for fatty deposits
in the liver and was used to delineate molecular events
associated with fatty liver. TCPOBOP and Wy-14,643 had
no effect on PGC-1a (ofﬁcial symbol, PPARGC1A)
expression, whereas MCDD signiﬁcantly induced this gene
associated with lipid metabolism (Figure 1A).
To examine the effect of RB loss on tissue homeostasis,
mice were sacriﬁced and livers were weighed before histo-
logic processing (Figure 1B). As expected, Wy-14,643
signiﬁcantly increased liver mass (P < 0.05). MCDD had
little overall effect on liver weight. In neither case was liver
weight signiﬁcantly inﬂuenced by RB1 status. At both 72
and 216 hours after TCPOBOP exposure, RB-deﬁcient and
control mice displayed a statistically signiﬁcant (P < 0.05)
increase in liver weight compared with vehicle-treated mice
(Figure 1B). Further histologic analysis of liver sections
after treatments yielded expected phenotypes (Figure 1C).
MCDD resulted in massive accumulation of fat deposits in
the livers generating steatosis, whereas Wy-14,643 had
minimal effect on liver histologic ﬁndings but induced mild
dysplasia with some nuclear atypia. TCPOBOP induced
signiﬁcant dysplasia with pleomorphic nuclear features. In
no case were these histologic manifestations signiﬁcantly
altered by RB status (Figure 1C).
RB Loss Speciﬁcally Uncouples the Cellular Response to
TCPOBOP
Cell cycle progression was measured in liver tissue to better
elucidate the inﬂuence of RB1 status on the phenotypic
response to each of the stresses. All animals were labeled
with BrdU 1 hour before sacriﬁce. Despite the profound
effect of Wy-14,643 on liver size, it resulted in modest in-
duction of proliferation at 72 hours after treatment. This
increase in proliferation was not affected by RB1 status
(Figure 2, A and B). The proliferative response was tran-
sient; at 2 weeks after Wy-14,643 treatment, livers had
returned to a basal level of proliferation via BrdU analysis
(data not shown). Mice given MCDD exhibited a limited1856increase in proliferation as determined by BrdU incorpora-
tion, which was similarly unaffected by the presence of RB
(Figure 2, A and B). These combined data suggest that RB1
status has little effect on the liver under the effects of Wy-
14,643 or MCDD. In contrast, TCPOBOP-treated livers
had signiﬁcant (P < 0.05) deregulation of proliferation with
RB-deﬁcient livers demonstrating a twofold increase in
BrdU incorporation compared with the RB-sufﬁcient livers.
This effect was transient, and all proliferation returned to
basal levels by 216 hours after treatment (Figure 2, A and
B). However, livers remained large and exhibited little
apoptotic cell death after TCPOBOP treatment (not shown).
These data suggest that RB deﬁciency has a particular effect
on the response to TCPOBOP.TCPOBOP Impinges on RB Pathways in a Unique
Fashion
Prior work has described pathways through which discrete
stresses affect proliferative pathways to drive cell cycle
progression.13,24 To understand the signaling involved distal
to TCPOBOP exposure, levels of key proteins involved in
cell cycle control in the liver were evaluated. Consistent
with the enhanced proliferation, we observed that the
E2F-regulated protein PCNA was signiﬁcantly stimulated inajp.amjpathol.org - The American Journal of Pathology
Figure 3 Mice with RB-sufﬁcient and RB-deﬁcient livers were treated with TCPOBOP for 72 hours. A: Liver extracts were prepared and immunoblotted for
the indicated proteins; all samples were analyzed in duplicate. B: Mice with RB-sufﬁcient and RB-deﬁcient livers were treated with TCPOBOP, DEN, or CCl4 and
sacriﬁced at the indicated time points. Liver extracts were prepared and immunoblotted for the indicated proteins; all samples were analyzed in duplicate. C:
Hepatocyte ploidy was measured by ﬂow cytometry. D: Mitosis measured by phospho-histone H3 staining. Data are from four mice in each group and represent
means  SD (C and D).
RB Suppresses Xenobiotic CarcinogenesisRB-deﬁcient livers exposed to TCPOBOP, relative to
RB-sufﬁcient controls (Figure 3A). We have previously
reported that two pathways lead to the stimulation of E2F
target genes, one being the canonical regenerative pathways
that diminish p130 levels and yield conventional mitogenic
signaling and the other being a genotoxic-induced pathway
whereby RB controls the levels of E2F proteins to specif-
ically yield cell cycle entry in RB-deﬁcient models.13 ForThe American Journal of Pathology - ajp.amjpathol.orgthese analyses, we compared TCPOBOP and either DEN, a
genotoxic carcinogen, or CCl4, which yields regeneration.
TCPOBOP functioned similarly to CCl4 in leading to the
attenuation of p130 status irrespective of RB status
(Figure 3B). However, TCPOBOP had a relatively modest
effect on E2F1 expression, and there was only effective
induction of the MCM7 protein in RB-deﬁcient liver tissue,
similar to the PCNA expression data. These data indicateFigure 4 Mice were treated in the long-term
with TCPOBOP and resultant livers excised after
29 weeks. A: Liver weight was determined for all
mice. B: Representative images indicate that
control tumors lack spontaneous tumors after 29
weeks regardless of RB status. C: Representative
images indicate that RB-deﬁcient livers exposed to
TCPOBOP exhibit multiple large tumors on visual
inspection. D: Quantitation of BrdU staining of
liver lesions in RB-positive versus RB-negative
tumors. E: Representative tissues were stained
for H&E and BrdU incorporation. Dashed line
represents approximate border between tumor and
normal tissue. Data are presented as means  SD
(A and D). *P < 0.05 versus TCPOBOP-treated RB-
sufﬁcient livers as determined by Welch’s t-test.
Original magniﬁcation: 20 (E).
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Reed et althat TCPOBOP uses a signaling pathway more similar to
regeneration to yield cell cycle entry but in an RB-dependent
fashion. Consistent with this conclusion, TCPBOP-treated
cells maintain appropriate ploidy (Figure 3C) and progress
into mitosis (Figure 3D), which is indicative of regenerative
signals as opposed to genotoxic stresses.
RB Loss Sensitizes to TCPOBOP-Mediated Tumor
Development
To investigate whether RB functions as a tumor suppressor in
response to long-term TCPOBOP exposure, mice were
administered TCPOBOP on a biweekly basis for 24 weeks.
Treated mice were not exposed to TCPOBOP for the next 5
weeks to allow for recovery and tumor progression. Before
sacriﬁce, mice received a single injection of BrdU. After
sacriﬁce, livers were excised, photographed, and weighed.
As can be seen in Figure 4A, after treatment, both RB-
sufﬁcient and RB-deﬁcient livers weighed signiﬁcantly
(P < 0.05) more than untreated control livers; however, this
was especially evident in RB-deﬁcient livers, where a
twofold increase was seen when compared with RB-
sufﬁcient TCPOBOP-treated livers. Visual examination
revealed that the increased liver weight was due to enhanced
tumor burden (Figure 4, B and C). No tumors were visible in
animals not treated with TCPOBOP, regardless of RB status.
Although the remnant liver tissue remained quiescent, as
determined by BrdU incorporation (Figure 4D), all long-term
TCPOBOP-treated livers exhibited dysplasia, with RB-
deﬁcient liver tissue exhibiting signiﬁcant accumulation of
hepatocytes with abnormally large nuclei (Figure 4E). In
contrast, the adenomas and HCCs that arose in the RB-
deﬁcient livers were highly proliferative (Figure 4E). These
data indicate a profound effect of RB loss on tumorigenesis
driven by the nongenotoxic carcinogen TCPOBOP.Discussion
RB loss occurs at a relatively high frequency in liver cancer.
Because of the role of RB in cell cycle control, it has been
expected that RB deﬁciency would have a general effect on
the response to carcinogenic stresses. However, this study
suggests speciﬁcity of RB function that would not have
been heretofore expected.
Mice that harbor speciﬁc deletion in the liver have been
found to develop tumors under the exposure of genotoxic
carcinogens. However, RB loss in the presence of non-
genotoxic carcinogens has, to our knowledge, never been
explored. In the analysis of regenerative processes, we
previously demonstrated no effect of RB loss on cell cycle
control in terms of either cell cycle entry or exit.13 Similarly,
we found no discernible effect of RB loss on the prolifer-
ative response to peroxisome proliferators or diets inducing
steatosis (Figure 2). There are multiple explanations for
these ﬁndings, but perhaps the most likely explanation is the1858myriad of overlapping cell cycle pathway regulators, in-
cluding CDK inhibitors (eg, p27Kip1) and RB-related pro-
teins (eg, p130), that maintain appropriate control of cellular
proliferation in the absence of RB. Thus, the effect of RB
loss is limited to speciﬁc responses and contexts.
Human HCC is particularly challenging to mimic in mouse
models. In part, this is due to the absence of good models for
hepatitis C viruse and hepatitis B virusedriven
carcinogenesis.17e19 However, the key underlying feature of
most HCCs is cirrhosis, which can be emulated through a va-
riety of long-term exposures.1,17e19 The xenobiotic constitutive
androstane receptor agonist agent TCPOBOP is similar in
function to the tumor promoter phenobarbital.25 The underlying
mechanism through which such agents promote tumor devel-
opment is somewhat obscure, although clearly the repeated
proliferative cycles induced by TCPOBOP serve to promote
tumor development.26 In the absence of a genotoxic stress (eg,
DEN), TCPOBOP is a relatively weak carcinogen, and as
shown here only relatively low-grade adenomas arose in the
RB-sufﬁcient mice (Figure 4). Loss of RB strikingly synergizes
with TCPOBOP in tumor development, yielding massive
conversion to HCC in a large fraction of the liver tissue. On the
basis of the acute response to TCPBOPOP, we would suspect
that increased proliferative response in RB-deﬁcient livers un-
derlies this feature of disease. However, because quiescence
readily develops after the cessation of TCPOBOP treatment, the
genesis of HCC must reﬂect genetic and epigenetic alterations
that drive HCC. In this fashion, this model mimics the pattern of
long-term exposures in humans and suggests that the early loss
of RB in a preneoplastic lesion would promote the acquisition
of additional mutational events that facilitate the development
of HCC. Because TCPOBOP of itself is not particularly gen-
otoxic, these ﬁndings would suggest that RB loss can function
as an initiator to drive the development of disease. This concept
is borne out in clinical specimens, where tumors that lack RB
(13q14 loss of heterozygosity) are associated with chromosome
instability and poor overall outcome.27
These data reinforce the concept that RB loss has a spe-
ciﬁc effect on liver biology, leading to aberrant response to a
subset of stresses. We found that RB controls the response
to long-term exposure to nongenotoxic carcinogens that
induce cirrhosis. In such contexts, RB serves as a potent
tumor suppressor. Importantly, this transcends multiple
carcinogenic stresses and supports the contention that RB
deﬁciency is an important participant in the suppression of
liver tumor development.
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